Femke Mathot

9 MSC gene expression on nerve substitutes 163 67-74. 45. Taioli F, Cabrini I, Cavallaro T, Acler M, Fabrizi GM. Inherited demyelinating neuropathies with micromutations of peripheral myelin protein 22 gene. Brain 2011: 134: 608-17. 46. Caillaud M, Richard L, Vallat JM, Desmouliere A, Billet F. Peripheral nerve regeneration and intraneural revascularization. Neural Regen Res 2019: 14: 24-33. 47. Cutting CB, McCarthy JG. Comparison of residual osseous mass between vascularized and nonvascularized onlay bone transfers. Plastic & Reconstructive Surgery 1983: 72: 672-5. 48. Parrinello S, Napoli I, Ribeiro S, et al. EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting. Cell 2010: 143: 145-55. 49. Nishida Y, Yamada Y, Kanemaru H, et al. Vascularization via activation of VEGF-VEGFR signaling is essential for peripheral nerve regeneration. Biomed Res 2018: 39: 287-94. 50. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al. Involvement of endothelial PE- CAM-1/CD31 in angiogenesis. Am J Pathol 1997: 151: 671-7. 51. Koopmans G, Hasse B, Sinis N. Chapter 19: The role of collagen in peripheral nerve repair. Int Rev Neurobiol 2009: 87: 363-79. 52. Hubert T, Grimal S, Carroll P, Fichard-Carroll A. Collagens in the developing and diseased ner- vous system. Cell Mol Life Sci 2009: 66: 1223-38. 53. Miosge N, Gotz W, Sasaki T, et al. The extracellular matrix proteins fibulin-1 and fibulin-2 in the early human embryo. Histochem J 1996: 28: 109-16. 54. Maselli RA, Arredondo J, Ferns MJ, Wollmann RL. Synaptic basal lamina-associated congenital myasthenic syndromes. Ann N Y Acad Sci 2012: 1275: 36-48. 55. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of Age: CD96 Emerges as Modu- lator of Immune Responses. Front Immunol 2018: 9: 1072. 56. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone mar- row-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Jama 2012: 308: 2369-79. 57. Hare JM, DiFede DL, Rieger AC, et al. Randomized Comparison of Allogeneic Versus Autol- ogous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol 2017: 69: 526-37. 58. Mushtaq M, DiFede DL, Golpanian S, et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendo- cardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 2014: 7: 769-80. 59. Shen H, Wang Y, Zhang Z, et al. Mesenchymal Stem Cells for Cardiac Regenerative Therapy: Optimization of Cell Differentiation Strategy. Stem Cells Int 2015: 2015: 524756. 60. Koga H, Muneta T, Nagase T, et al. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. Cell Tissue Res 2008: 333: 207-15. 61. Sutton MT, Fletcher D, Ghosh SK, et al. Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. Stem Cells Int 2016: 2016: 5303048. 62. Sutton MT, Fletcher D, Episalla N, et al. Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis. J Stem Cell Res Ther 2017: 7. 63. Orbay H, Uysal AC, Hyakusoku H, Mizuno H. Differentiated and undifferentiated adipose-de- rived stem cells improve function in rats with peripheral nerve gaps. J Plast Reconstr Aesthet Surg 2011. 64. Tomita K, Madura T, Sakai Y, et al. Glial differentiation of human adipose-derived stem cells: implications for cell-based transplantation therapy. Neuroscience 2013: 236: 55-65. 65. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015: 2015: 394917.